• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OBIO

    Orchestra BioMed Holdings Inc.

    Subscribe to $OBIO
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    IPO Year: 2020

    Exchange: NASDAQ

    Recent Analyst Ratings for Orchestra BioMed Holdings Inc.

    DatePrice TargetRatingAnalyst
    3/20/2025$12.00Buy
    BTIG Research
    1/2/2025$16.00Overweight
    Barclays
    8/22/2024$14.00Buy
    H.C. Wainwright
    7/25/2024$15.00Buy
    B. Riley Securities
    1/19/2024$14.00Buy
    Jefferies
    2/24/2023$15.00Overweight
    Piper Sandler
    2/7/2023$20.00Buy
    Chardan Capital Markets
    See more ratings

    Orchestra BioMed Holdings Inc. SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.

      SCHEDULE 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      5/1/25 5:41:46 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Orchestra BioMed Holdings Inc.

      DEFA14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      4/30/25 4:18:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Orchestra BioMed Holdings Inc.

      DEF 14A - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      4/30/25 4:16:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      4/29/25 9:18:55 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-K filed by Orchestra BioMed Holdings Inc.

      10-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      3/31/25 4:16:09 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      3/3/25 8:01:10 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 8-K filed by Orchestra BioMed Holdings Inc.

      8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      2/25/25 4:30:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 filed by Orchestra BioMed Holdings Inc.

      S-8 - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      2/19/25 4:30:59 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Orchestra BioMed Holdings Inc.

      SCHEDULE 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      2/14/25 4:06:04 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      2/5/25 8:18:45 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    Orchestra BioMed Holdings Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Orchestra BioMed with a new price target

      BTIG Research initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $12.00

      3/20/25 8:00:48 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Barclays initiated coverage on Orchestra BioMed with a new price target

      Barclays initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $16.00

      1/2/25 8:04:57 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • H.C. Wainwright initiated coverage on Orchestra BioMed with a new price target

      H.C. Wainwright initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00

      8/22/24 7:33:07 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • B. Riley Securities initiated coverage on Orchestra BioMed with a new price target

      B. Riley Securities initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $15.00

      7/25/24 8:24:04 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Jefferies initiated coverage on Orchestra BioMed with a new price target

      Jefferies initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00

      1/19/24 8:10:27 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Piper Sandler initiated coverage on Orchestra BioMed with a new price target

      Piper Sandler initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $15.00

      2/24/23 9:13:05 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chardan Capital Markets initiated coverage on Orchestra BioMed with a new price target

      Chardan Capital Markets initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $20.00

      2/7/23 7:20:24 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    Orchestra BioMed Holdings Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

      SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      8/7/24 5:19:57 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

      SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      8/7/24 5:16:55 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Orchestra BioMed Holdings Inc.

      SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      7/17/24 4:32:50 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    Orchestra BioMed Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

      Secured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total for this condition to 120 patentsPatent estate covering atrioventricular interval modulation ("AVIM") therapy now includes 46 issued U.S. patents and 91 patents outside the U.S. that collectively comprise over 2100 claims related to the treatment of hypertension as well as heart failureHeart failure pipeline program now protected by an additional 17 issued global patents FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk, including those at risk of heart fa

      5/7/25 8:30:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

      Orchestra BioMed's Virtue® Sirolimus AngioInfusion Balloon™ ("Virtue SAB") is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device DesignationsThe Virtue Trial will be the first U.S. IDE head-to-head randomized evaluation of a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) for the treatment of coronary in-stent restenosis ("ISR")Robust non-inferiority trial is designed to provide a clear pathway to regulatory approval as well as potentially showcase clinical advantages of Virtue SABWith the amended IDE approved by the FDA, Orchestra BioMed is currently targeti

      4/29/25 9:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

      NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company's participation appear below: Chardan Capital's Trending Issues in Drug Development Conference – April 29, 2025 (Virtual) David Hochman, Orchestra BioMed's Chairman and Chief Executive Officer, will participate in a fireside chat with Keay Nakae, Senior Research Analyst, Chardan on the topic of "Data & Reg

      4/28/25 4:30:00 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

      FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular riskHRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac functionSymposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE:MDT) NEW HOPE, Pa., April 23, 2025 (GLOBE

      4/23/25 9:00:13 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

      First fully absorbable, sutureless closure system designed for large-bore procedures aims to improve procedural efficiency and patient outcomes in structural heart interventions Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced European CE mark approval of the PerQseal® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer. Leveraging Vivasure's PerQseal technology, the PerQseal Elite vascular closure system is designed exclusively for sutureless and fully absorbable large-bore closure follow

      4/22/25 9:36:00 AM ET
      $HAE
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

      Breakthrough Device Designation ("BDD") applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular riskBDD also encompasses pacemaker-indicated patients with uncontrolled hypertension who are the focus of the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE:MDT)BDD status provides accelerated FDA engagement and reviews for AVIM therapy; it also supports potential pathways to secure higher reimbursement for AVIM-enabled devices in the future NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra

      4/22/25 7:00:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed to Present at Upcoming Investor Conferences

      NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences. Details on the Company's presence at these conferences are shown below. Presentations TD Cowen 45th Annual Healthcare ConferenceFormat: Corporate Presentation Date: March 3, 2025Time: 2:30 PM ETWebcast: https://wsw.com/webcast/cowen177/obio/2014707 Barclays 27th Annual Global Healthcare ConferenceFormat: Fire

      2/20/25 8:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

      The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a

      2/18/25 8:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

      Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failureHypertension is the leading cause of diastolic dysfunction; both conditions are common in older patients and contribute to the development of heart failure NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefi

      2/12/25 10:43:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    Orchestra BioMed Holdings Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Rtw Investments, Lp bought $149,201 worth of shares (49,900 units at $2.99) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      5/1/25 8:18:11 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Rtw Investments, Lp bought $126,500 worth of shares (50,000 units at $2.53) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/29/25 5:16:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P bought $18,640 worth of shares (4,000 units at $4.66), increasing direct ownership by 0.70% to 579,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      12/26/24 5:46:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Taylor Andrew Lawrence bought $4,830 worth of shares (1,000 units at $4.83), increasing direct ownership by 0.29% to 344,960 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      12/20/24 8:30:15 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P bought $24,550 worth of shares (5,000 units at $4.91), increasing direct ownership by 0.88% to 575,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      12/19/24 8:30:09 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P bought $47,905 worth of shares (10,000 units at $4.79), increasing direct ownership by 0.44% to 570,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      9/26/24 8:15:12 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P bought $14,600 worth of shares (2,500 units at $5.84), increasing direct ownership by 0.44% to 567,998 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      8/15/24 5:30:54 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P bought $6,950 worth of shares (1,000 units at $6.95) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      6/26/24 4:15:13 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Little William Reed bought $28,000 worth of shares (4,000 units at $7.00), increasing direct ownership by 1% to 307,859 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      6/3/24 4:15:30 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Hochman David P bought $24,950 worth of shares (5,000 units at $4.99) (SEC Form 4) (Amendment)

      4/A - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      5/21/24 9:15:57 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    Orchestra BioMed Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Rtw Investments, Lp bought $149,201 worth of shares (49,900 units at $2.99) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      5/1/25 8:18:11 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Rtw Investments, Lp bought $126,500 worth of shares (50,000 units at $2.53) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/29/25 5:16:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P was granted 98,333 shares, increasing direct ownership by 20% to 579,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/4/25 9:44:39 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Aiello Joshua

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/4/25 9:40:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Sherman Darren was granted 115,708 shares, increasing direct ownership by 16% to 849,680 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/4/25 9:39:18 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Taylor Andrew Lawrence was granted 84,000 shares, increasing direct ownership by 24% to 428,960 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/4/25 9:37:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Principal Accounting Officer Aiello Joshua covered exercise/tax liability with 278 shares, decreasing direct ownership by 6% to 4,722 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      3/28/25 8:08:41 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P covered exercise/tax liability with 80,080 shares, decreasing direct ownership by 14% to 499,418 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      3/7/25 7:32:47 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Cleary Chris was granted 10,155 shares (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      2/5/25 4:16:30 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Cleary Chris

      3 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      2/5/25 4:15:13 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    Orchestra BioMed Holdings Inc. Financials

    Live finance-specific insights

    See more
    • Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

      Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc

      9/19/23 7:30:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    Orchestra BioMed Holdings Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

      The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a

      2/18/25 8:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

      Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

      2/5/25 8:00:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors

      John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors Most recently, Mr. Mack served as Medtronic's President of Cardiac Surgery; Previous Medtronic roles include Vice President, Business Development, Strategy & Portfolio Management NEW HOPE, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of John Mack to its Board of Directors, effective as of July 29, 2024. Mr. Mack brings over 30 years

      7/30/24 8:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

      David Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers; formerly Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott VascularMr. Pacitti brings nearly 30 years of experience in cardiovascular device and procedural imaging experience to the Orchestra BioMed Board of Directors after previously serving as a strategic advisor during the formation of the company NEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward shar

      3/26/24 8:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

      FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi

      9/6/23 5:00:42 PM ET
      $MOTS
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

      U.S. Food and Drug Administration ("FDA") granted Investigational Device Exemption ("IDE") approval with conditions for Virtue SAB® coronary in-stent restenosis ("ISR") U.S. pivotal study (in collaboration with Terumo Corporation ("Terumo")); study expected to start before the end of 2023BackBeat CNT™ global pivotal study in hypertensive pacemaker patients (in collaboration with Medtronic) on track for initiation in the second half of 2023 NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships

      8/10/23 4:34:21 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

      Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role Andrew Taylor joins as Chief Financial Officer (CFO) with over 20 years of CFO experience with emerging growth companies, the last 15 of which were spent in the medical device sector NEW HOPE, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-rewa

      6/7/23 8:30:00 AM ET
      $MOTS
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

      Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 millionBackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation in the second half of 2023 in collaboration with MedtronicVirtue SAB® U.S. pivotal study in coronary in-stent restenosis ("ISR") start planned for the second half of 2023 in collaboration with Terumo NEW HOPE, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2023 financial r

      5/12/23 9:15:18 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care